Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DiaMedica Therapeutics Inc.

www.diamedica.com

Latest From DiaMedica Therapeutics Inc.

Finance Watch: Moderna Launches Biggest Biopharma IPO Ever As US Market Resets Expectations

Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.

Financing Business Strategies

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Financing Asia Pacific

Asia Deal Watch: Alvotech Signs On To Biosimilar Manufacturing JV In China

With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.

Deals Commercial

Pipeline Watch: Phase III Starts With Atezolizumab, CNTX-4975 And WTX101

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Diabex Inc.
  • DiaMedica Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • DiaMedica Therapeutics Inc.
  • Senior Management
  • Rick Pauls, Pres. & CEO
    Scott Kellen, CFO
    Todd Verdoorn, PhD, CSO
    Todd Alcorn, CMO
    Paul Papi, VP, Bus. Dev.
  • Contact Info
  • DiaMedica Therapeutics Inc.
    Phone: (763) 496-5454
    2 Carlson Pkwy.
    Ste. 260
    Minneapolis, MN 55447
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register